Cobicistat is a pharmacokinetic enhancer classified as a potent cytochrome P450 3A (CYP3A) inhibitor, used clinically to increase the systemic exposure of antiretroviral protease inhibitors like atazanavir… Read more







![Chemical structure of (S)-Ethyl 2-[3-(2-Isopropyl-thiazol-4-ylmethyl)-3-methylureido]-4-morpholin-4-yl-butanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1247119-35-2-S-Ethyl-2-3-2-Isopropyl-thiazol-4-ylmethyl-3-methylureido-4-morpholin-4-yl-butanoate.png&w=3840&q=75)



































Cobicistat is a pharmacokinetic enhancer classified as a potent cytochrome P450 3A (CYP3A) inhibitor, used clinically to increase the systemic exposure of antiretroviral protease inhibitors like atazanavir and darunavir in the treatment of HIV-1 infection. This category offers a comprehensive selection of Cobicistat reference standards, including pharmacopeial and non-pharmacopeial impurities, synthetic intermediates, degradation products, and stable isotope labelled compounds. These materials serve as essential tools for pharmaceutical laboratories engaged in rigorous method development, impurity profiling, and quality control testing. By providing structurally characterized reference standards, the collection supports the accurate identification and quantification of process-related impurities and degradation products during stability assessments. The availability of stable isotope labelled versions further enables precise analytical measurements via techniques such as LC-MS, facilitating compliance with international regulatory guidelines throughout the pharmaceutical development and manufacturing lifecycle of this important HIV therapy.